Targeted therapies in rheumatoid arthritis: Focus on rituximab.
about
Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor.Long-term persistence with rituximab in patients with rheumatoid arthritis.
P2860
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
@en
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
@nl
type
label
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
@en
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
@nl
prefLabel
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
@en
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
@nl
P2093
P2860
P1476
Targeted therapies in rheumatoid arthritis: Focus on rituximab
@en
P2093
J M van Laar
T W Huizinga
P2860
P304
P577
2007-12-01T00:00:00Z